October 22, 2025 – Talk Bio

Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial

2 days ago talkbio0Tagged Alector, Clinical trial failure, Drug Development, Latozinemab, Phase 3 trial, Pick Disease of the Brain, Presenile dementia, Progranulins, SmithKline Beecham

Alector; GSK; latozinemab; dementia; frontotemporal dementia; Phase 3 trial; clinical trial failure; progranulin; drug development

Sanofi’s efdoralprin alfa (INBRX-101) achieves all endpoints in Phase 2 alpha-1 antitrypsin deficiency (AATD) trial

2 days ago talkbio0Tagged Acquisition, alpha 1-Antitrypsin Deficiency, efdoralprin alfa, INBRX-101, Inhibrx, Phase 2, plasma-derived therapy, Rare Diseases, sanofi, Zemaira

Sanofi; efdoralprin alfa; INBRX-101; AATD; alpha-1 antitrypsin deficiency; Phase 2; Inhibrx; acquisition; rare disease; plasma-derived therapy; Zemaira

Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B

2 days ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug Conjugates, Cancer Therapeutic Procedure, co-development, global strategic partnership, IBI343, IBI363, Innovent Biologics, Neoplasms, Payments, Takeda

Takeda; Innovent Biologics; global strategic partnership; bispecific antibody; antibody-drug conjugate (ADC); oncology; IBI363; IBI343; IBI3001; $1.2 billion upfront; $11.4 billion total deal; cancer therapy; co-development; milestone payments

FDA Staffing Data Reveal Historic Departures in Fiscal 2025

2 days ago talkbio0Tagged CBER, CDER, departures, Disruption, Drug Approval, fiscal, layoffs, Organization administrative structures, Regulatory Impact, United States Food and Drug Administration, Workforce - population group

FDA; staffing; departures; fiscal 2025; layoffs; regulatory impact; CDER; CBER; drug approval delays; organizational disruption

Apptronik Raises $350 Million Series A to Scale AI Humanoid Robot Production

2 days ago talkbio0Tagged AI humanoid robots, Apollo robot, Apptronik, Funding, Robotics, Series A, venture capital

Apptronik; Series A funding; AI humanoid robots; Apollo robot; venture capital; robotics

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

3 days ago talkbio0Tagged AFFIRM-1 phase 3 trial, BNC210, Clinical trial failure, Discontinuation (procedure), Merck, Neuphoria, Neuroscience discipline, Partnership, Phobia, Social, Post-Traumatic Stress Disorder, Programs - Publication Format, Schizophrenia

Neuphoria Therapeutics; BNC210; social anxiety disorder; AFFIRM-1 phase 3 trial; clinical trial failure; program discontinuation; PTSD; Merck partnership; Minerva Neurosciences; schizophrenia therapy

GSK, Spero Reveal Full Phase 3 Data for Oral Antibiotic Tebipenem HBr; Regulatory Filing Set for End of 2025

3 days ago talkbio0Tagged Complicated, cUTIs, HBr, IDWeek, non-inferiority, oral carbapenem, Phase 3 PIVOT-PO trial, Regulatory Filing, SmithKline Beecham, Spero Therapeutics, Submission, United States Food and Drug Administration, Urinary tract infection

GSK; Spero Therapeutics; tebipenem HBr; oral carbapenem; Phase 3 PIVOT-PO trial; complicated urinary tract infections (cUTIs); non-inferiority; IDWeek 2025; regulatory filing; FDA submission

Elevara Raises $70M to Advance Novel Rheumatoid Arthritis Treatment Targeting Synovial Fibroblasts

3 days ago talkbio0Tagged CDK4/6 inhibitor, Chronic inflammatory disorder, Clinical Trials, Elevara Medicines, ELV001, Forbion, Partner in relationship, Pharma, Rheumatoid Arthritis, Series A financing, Sofinnova, synovial fibroblasts, Teijin

Elevara Medicines; Series A financing; rheumatoid arthritis; ELV001; CDK4/6 inhibitor; synovial fibroblasts; Teijin Pharma; clinical trial; chronic inflammatory diseases; Forbion; Sofinnova Partners

Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline

3 days ago talkbio0Tagged Acquisition, Anti-BTN3A Agonistic Monoclonal Antibody ICT01, BTN3A, butyrophilin superfamily, ImCheck Therapeutics, Immunotherapy, Ipsen, Leukemia, Myelocytic, Acute, Monoclonal Antibodies, Oncology Pipeline

Ipsen; ImCheck Therapeutics; acquisition; €350 million; €1 billion deal; immunotherapy; oncology pipeline; butyrophilin superfamily; ICT01; acute myeloid leukemia; monoclonal antibody; BTN3A

Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales

3 days ago talkbio0Tagged Appointments, Arginine Vasopressin-Neurophysin II Preproprotein, board of directors, commercialization, global sales, Health care facility, Inspira Technologies, Johnson & Johnson, Leadership, Mike Hershkovitz

Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors